Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 14/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402789 | 0.84 | LCK (0.52) | CA1CA2LCKPI4KB | |
| SCHEMBL27459069 | 0.83 | CA1 (0.42) | CA1CA2LCKPI4KB | |
| SCHEMBL367235 | 0.83 | CA1 (0.47) | CA1CA2LCKPI4KB | |
| SCHEMBL1268366 | 0.83 | LCK (0.46) | CA1CA2LCKPI4KB | |
| SCHEMBL31214147 | 0.81 | CA1 (0.42) | CA1CA2LCKPI4KB | |
| SCHEMBL20422004 | 0.79 | DYRK1A (0.44) | — | |
| SCHEMBL21665751 | 0.77 | LCK (0.46) | CA1CA2LCKPI4KB | |
| SCHEMBL21645365 | 0.77 | MEN1 (0.34) | — | |
| SCHEMBL5408019 | 0.75 | LCK (0.46) | CA1CA2LCKPI4KB | |
| SCHEMBL21359065 | 0.75 | HPGD (0.47) | CA1CA2PI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275728-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12180205-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240308995-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2024-09-19 | — | — | US | disclosed |
| EP-4419551-A1 | O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY | Eli Lilly and Company (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-112469476-B | 5-Methyl-4-fluoro-thiazol-2-yl compounds | 伊莱利利公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11999726-B2 | 5-methyl-4-fluoro-thiazol-2-yl compounds | ELI LILLY AND COMPANY | 2024-06-04 | — | — | US | disclosed |
| CN-118139880-A | O-linked N-acetylglucosamine hydrolase (OGA) inhibitor combination therapy | 伊莱利利公司 | 2024-06-04 | — | — | CN | disclosed |
| US-11839654-B2 | Combination therapy | ELI LILLY AND COMPANY (US) | 2023-12-12 | — | — | US | disclosed |
| US-11839654-B2 | Combination therapy | ELI LILLY AND COMPANY (US) | 2023-12-12 | — | — | US | disclosed |
| WO-2023070064-A1 | O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2020028141-A1 | COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2020-02-06 | — | — | WO | disclosed |
| CN-110650957-A | 5-methyl-1, 3, 4-oxadiazol-2-yl compounds | 伊莱利利公司 | 2020-01-03 | — | — | CN | disclosed |
| US-10377750-B2 | 5-methyl-1,3,4-oxadiazol-2-yl compounds | ELI LILLY AND COMPANY (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377750-B2 | 5-methyl-1,3,4-oxadiazol-2-yl compounds | ELI LILLY AND COMPANY (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180339984-A1 | 5-METHYL-1,3,4-OXADIAZOL-2-YL COMPOUNDS | LILLY CO ELI (US) | 2018-11-29 | — | — | US | disclosed |
| WO-2018217558-A1 | 5-METHYL-1,3,4-OXADIAZOL-2-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2018-11-29 | — | — | WO | disclosed |
| US-10081625-B2 | 5-methyl-1,2,4-oxadiazol-3-yl compounds | ELI LILLY AND COMPANY (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180215751-A1 | 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215751-A1 | 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2018-08-02 | — | — | US | disclosed |
| WO-2018140299-A1 | N-[4-FLUORO-5-[[(2S,4S)-2-METHYL-4-[(5-METHYL-1,2,4-OXADIAZOL-3-YL)METHOXY]-1-PIPERIDYL]METHYL]THIAZOL-2-YL]ACETAMIDE AS OGA INHIBITOR | ELI LILLY AND COMPANY (US) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215751-A1 | 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUNDS | PSEN1, PSEN2, MAPT | CA1 1098/4885CA2 2238/4885LCK 930/4885 |
| US-12180205-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | MGAT3, MAN2A1, ENGASE | CA1 797/4885CA2 293/4885LCK 3944/4885 |
| US-20240308995-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | MGAT3, MAN2A1, ENGASE | CA1 797/4885CA2 293/4885LCK 3944/4885 |
| US-10081625-B2 | 5-methyl-1,2,4-oxadiazol-3-yl compounds | PSEN1, PSEN2, MAPT | CA1 1098/4885CA2 2238/4885LCK 930/4885 |
| US-10377750-B2 | 5-methyl-1,3,4-oxadiazol-2-yl compounds | PSEN1, PSEN2, MAPT | CA1 1095/4885CA2 2216/4885LCK 895/4885 |
| US-20180339984-A1 | 5-METHYL-1,3,4-OXADIAZOL-2-YL COMPOUNDS | PSEN1, PSEN2, MAPT | CA1 1095/4885CA2 2216/4885LCK 895/4885 |
| US-11839654-B2 | Combination therapy | MAPT, OGA, OAT | CA1 331/4885CA2 1249/4885LCK 3514/4885 |
| US-12275728-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | MGAT3, MAN2A1, ENGASE | CA1 797/4885CA2 293/4885LCK 3944/4885 |
| US-11999726-B2 | 5-methyl-4-fluoro-thiazol-2-yl compounds | MAPT, PSEN2, PSEN1 | CA1 1629/4885CA2 2499/4885LCK 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.